Evidence map›Paper›PMID 27412591›Full record

ArticleJournal of virology2016

Derivation and Characterization of Pathogenic Transmitted/Founder Molecular Clones from Simian Immunodeficiency Virus SIVsmE660 and SIVmac251 following Mucosal Infection.

Michael J Lopker, Gregory Q Del Prete, Jacob D Estes, Hui Li, Carolyn Reid, Laura Newman, Leslie Lipkey, Celine Camus, Juliet L Easlick, Shuyi Wang and 9 more

Open access · bronzeAbstract read
In one paragraph

Article in Journal of virology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
2.5field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 21 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Journal of virology · 2019
    Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 6 institutions in 1 country.

Michael J LopkerUniversity of Alabama at Birmingham, Birmingham, Alabama, USA.
Gregory Q Del PreteAIDS and Cancer Virus Program, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, Maryland, USA.
Jacob D EstesAIDS and Cancer Virus Program, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, Maryland, USA.
Hui LiPerelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Carolyn ReidAIDS and Cancer Virus Program, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, Maryland, USA.
Laura NewmanAIDS and Cancer Virus Program, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, Maryland, USA.
Leslie LipkeyAIDS and Cancer Virus Program, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, Maryland, USA.
Celine CamusAIDS and Cancer Virus Program, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, Maryland, USA.
Juliet L EaslickUniversity of Alabama at Birmingham, Birmingham, Alabama, USA.
Shuyi WangPerelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Julie M DeckerUniversity of Alabama at Birmingham, Birmingham, Alabama, USA.
Katharine J BarPerelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Gerald LearnPerelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Ranajit PalAdvanced BioScience Laboratories, Inc., Rockville, Maryland, USA.
Deborah E WeissBioqual, Rockville, Maryland, USA.
Beatrice H HahnPerelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Jeffrey D LifsonAIDS and Cancer Virus Program, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, Maryland, USA.
George M ShawPerelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Brandon F KeeleAIDS and Cancer Virus Program, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, Maryland, USA keelebf@mail.nih.gov.
University of Pennsylvania · USFrederick National Laboratory for Cancer Research · USLeidos (United States) · USUniversity of Alabama at Birmingham · USBioqual · USBioScience Laboratories (United States) · US

Funding

Virus and Antibody Gene Sequencing CoreP01AI131251 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI Kevin Wiehe · 2017 to 2026
$40.7M
Targeting 5' leader-encoded defective ribosomal products for HIV T cell vaccinesR01AI118549 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI SHAW, GEORGE M · 2016 to 2020
$3.6M
Penile transmission and neutralization of pathogenic SIVsmmR01AI094604 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI SHAW, GEORGE M · 2011 to 2015
$3.6M
Cloning, characterization and in vivo testing of mucosally transmitted SIVR33AI087383 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI SHAW, GEORGE M · 2013 to 2015
$1.4M
Cloning, characterization and in vivo testing of mucosally transmitted SIVR21AI087383 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI SHAW, GEORGE M · 2010 to 2011
$413k
CCR NIH HHS HHSN261200800001CNCI NIH HHS HHSN261200800001ENIAID NIH HHS P01 AI131251NIAID NIH HHS R01 AI094604NIAID NIH HHS R01 AI118549NIAID NIH HHS R21 AI087383NIAID NIH HHS R33 AI087383
6 · The paper itself

Abstract

unlabelledCurrently available simian immunodeficiency virus (SIV) infectious molecular clones (IMCs) and isolates used in nonhuman primate (NHP) models of AIDS were originally derived from infected macaques during chronic infection or end stage disease and may not authentically recapitulate features of transmitted/founder (T/F) genomes that are of particular interest in transmission, pathogenesis, prevention, and treatment studies. We therefore generated and characterized T/F IMCs from genetically and biologically heterogeneous challenge stocks of SIVmac251 and SIVsmE660. Single-genome amplification (SGA) was used to identify full-length T/F genomes present in plasma during acute infection resulting from atraumatic rectal inoculation of Indian rhesus macaques with low doses of SIVmac251 or SIVsmE660. All 8 T/F clones yielded viruses that were infectious and replication competent in vitro, with replication kinetics similar to those of the widely used chronic-infection-derived IMCs SIVmac239 and SIVsmE543. Phenotypically, the new T/F virus strains exhibited a range of neutralization sensitivity profiles. Four T/F virus strains were inoculated into rhesus macaques, and each exhibited typical SIV replication kinetics. The SIVsm T/F viruses were sensitive to TRIM5α restriction. All T/F viruses were pathogenic in rhesus macaques, resulting in progressive CD4(+) T cell loss in gastrointestinal tissues, peripheral blood, and lymphatic tissues. The animals developed pathological immune activation; lymphoid tissue damage, including fibrosis; and clinically significant immunodeficiency leading to AIDS-defining clinical endpoints. These T/F clones represent a new molecular platform for the analysis of virus transmission and immunopathogenesis and for the generation of novel "bar-coded" challenge viruses and next-generation simian-human immunodeficiency viruses that may advance the HIV/AIDS vaccine agenda. IMPORTANCE: Nonhuman primate research has relied on only a few infectious molecular clones for a myriad of diverse research projects, including pathogenesis, preclinical vaccine evaluations, transmission, and host-versus-pathogen interactions. With new data suggesting a selected phenotype of the virus that causes infection (i.e., the transmitted/founder virus), we sought to generate and characterize infectious molecular clones from two widely used simian immunodeficiency virus lineages (SIVmac251 and SIVsmE660). Although the exact requirements necessary to be a T/F virus are not yet fully understood, we generated cloned viruses with all the necessary characteristic of a successful T/F virus. The cloned viruses revealed typical acute and set point viral-load dynamics with pathological immune activation, lymphoid tissue damage progressing to significant immunodeficiency, and AIDS-defining clinical endpoints in some animals. These T/F clones represent a new molecular platform for studies requiring authentic T/F viruses.

Indexed as

GenotypePhenotypeAnimalsMacaca mulattaSimian Acquired Immunodeficiency SyndromeSimian Immunodeficiency VirusVirus Replication

Identifiers

PMID27412591
PMCPMC5021393
OpenAlexW2472210118

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.